生物医学研究および革新的な臨床治療戦略の追求において、ヒト化遺伝子モデルは最前線に立ち、ヒト生物学の複雑さを解明するユニークな視点を提供します。1つまたは複数の遺伝子をヒトの遺伝子に置き換えることにより、これらのモデルはヒト特有の構造ドメインを持つ完全なヒトタンパク質やキメラタンパク質を発現させることができます。この革新的なアプローチにより、研究者は前臨床研究環境で、薬物作用の微細なプロセスを前例のない精度でシミュレートすることが可能となります。
遺伝子ヒト化マウスの応用は、生物医学研究および臨床開発の重要な分野にわたります。特に、これらのモデルは腫瘍免疫療法において重要な役割を果たし、CAR-T細胞毒性の評価、さまざまな免疫療法アプローチのテストと検証、免疫療法戦略の組み合わせの探求、白血病幹細胞や白血病開始細胞のような難解な血液疾患ターゲットの特定など、ダイナミックなプラットフォームを提供します。
Cyagenスクリーニングおよび評価マウスモデルプラットフォームは、新薬開発をサポートするために、多様なターゲット遺伝子ヒト化モデルを提供する革新的な取り組みです。これには、hF11、B6-hCD47、B6-hPDL1-V、hCTLA4、B6-hIGHG1などが含まれます。遺伝子ヒト化マウスモデルの開発についてご質問がある場合は、お気軽にご連絡ください。弊社は、お客様の前臨床研究および薬剤発見を支援するため、カスタム遺伝子ヒト化モデルを作製します。
以下に、Cyagenスクリーニングおよび評価マウスモデルプラットフォームが提供する特定のヒト化ターゲット遺伝子疾患モデルの詳細な表を示します。これらのモデルは、B6-hCD47、B6-hPDL1-V、hCTLA4などの株を例に挙げ、生物医学革新の最前線を進む研究者にとって不可欠なツールとして機能します。各製品は、血液疾患から代謝疾患までの多様な疾患の理解に貢献し、革新的な治療法の開発と検証を支援するように慎重に設計されています。対応する製品名をクリックすると、マウスの詳細情報及び検証データをご覧いただけます。
製品番号 | モデル名 | 系統背景 | 適用分野 |
---|---|---|---|
C001413 | B6-hCTLA4 | C57BL/6NCya | Development and screening of CTLA4-targeted inhibitors/antibody drugs; Evaluation of the efficacy and safety of CTLA4-targeted inhibitors/antibody drugs; Assessment of tumor immunotherapy and research on immune system mechanisms; Research on autoimmune diseases. |
C001419 | B6-hCD47 | C57BL/6JCya | Development and screening of CD47-targeted inhibitors/antibody drugs; Evaluation of the efficacy and safety of CD47-targeted inhibitors/antibody drugs; Assessment of tumor immunotherapy and research on tumor immune evasion mechanisms. |
C001420 | B6-hPDL1-V | C57BL/6NCya | PDL1 (aka CD274)-targeted drug development, screening, and evaluation of efficacy and safety; Assessment of tumor immunotherapy; Research on the immune system and tumor immune evasion mechanisms. |
C001524 | hPD-1 | C57BL/6JCya | Immune checkpoints, tumor research. |
C001272 | hF11 | C57BL/6NCya | Factor XI deficiency, Hemophilia C (Rosenthal syndrome); related to blood clotting disorders |
C001400 | B6J-hANGPTL3 | C57BL/6JCya | Research on metabolic diseases such as atherosclerosis and hyperlipidemia; Studies on angiogenesis and endothelial cell adhesion; Development and screening of ANGPTL3-targeted drugs. |
C001401 | B6-hIGHG1 | C57BL/6NCya | Research on the mechanisms and pathways of immunoglobulins; Studies on the development and screening of IgG antibody drugs; Research on tumor proliferation, migration, and chemotherapy resistance; Studies on diseases such as chronic lymphocytic leukemia and amyloidosis. |
C001421 | B6-hGLP-1R | C57BL/6NCya | Research on the pathogenic mechanisms and drug development screening for obesity and type 2 diabetes; Study of other metabolic diseases such as cardiovascular and myocardial diseases; Research on neuroprotective effects in neurological diseases. |
C001492 | B6-hALB (HSA) | C57BL/6NCya | Development and evaluation of ALB-targeted drugs; Design and evaluation of albumin-based drug carriers; Research on ALB-related metabolic diseases. |
C001497 | B6-hCALCRL | C57BL/6JCya | Development of migraine treatment drugs, efficacy, and safety evaluation; Research on vascular biology and blood pressure regulation; Study of cell proliferation and apoptosis; Research on tumor growth inhibition and inflammation; Investigation of hematopoietic stem/progenitor cell generation and differentiation. |
C001500 | B6-hFCGR1 | C57BL/6NCya | Research on antibody-dependent cell-mediated cytotoxicity (ADCC); Study of immune system phagocytosis and antigen presentation; Assessment of affinity, pharmacology, and efficacy of IgG antibody drugs based on FcγRI receptors. |
C001523 | B6-hCALCA | C57BL/6JCya | Migraine drug development, efficacy, and safety evaluation; Vascular biology and blood pressure regulation research; Cell proliferation and apoptosis studies; Tumor growth inhibition and inflammation research; Hematopoietic stem/progenitor cell generation and differentiation research. |
C001520 | B6-hGDF15 | C57BL/6JCya | Heart disease, diabetes, anorexia, colorectal cancer, prostate cancer, etc. |
C001521 | B6-hLPA(CKI) | C57BL/6NCya | Arteriosclerosis, hyperlipidemia, thrombotic cardiovascular disease. |
C001522 | B6-hLPA(CKI)/Alb-cre | C57BL/6NCya | Arteriosclerosis, hyperlipidemia, thrombotic cardiovascular disease. |
C001325 | B6-hCD3 | C57BL/6NCya | Immunology Research; T Cell Activation and Antigen Recognition Research; Immunosuppressive Therapy Research for Autoimmune Diseases |
C001326 | BALB/c-hCD3 | BALB/cAnCya | Immunology Research; T Cell Activation and Antigen Recognition Research; Immunosuppressive Therapy Research for Autoimmune Diseases |
C001542 | H11-Alb-hLPA | C57BL/6NCya | Lp(a) cardiovascular disease, atherosclerosis, hyperlipidemia, thrombotic cardiovascular disease. |
CR004 | SD-Rosa-hAGT | Sprague-Dawley | Hypertension drug screening model. |
I001192 | H11-Alb-hHSD17B13 | C57BL/6JCya | Metabolic dysfunction-associated fatty liver disease (MAFLD), Metabolic dsfunction-asociated seatohepatitis (MASH). |
C001563 | Cd11b-hCD89 (FCAR) | C57BL/6NCya | Construction of IgA nephropathy (IgAN) model and efficacy evaluation; immune response and autoimmune mechanisms; research on tumors and infectious diseases. |
C001565 | B6-hIgA1 | C57BL/6NCya | Construction of IgA nephropathy (IgAN) model and efficacy evaluation; research on B cell development, immunoglobulin formation, and autoimmune mechanisms. |
C001584 | B6-hTFRC(CDS) | C57BL/6NCya | Research on iron metabolism disorders, neurodegenerative diseases, tumor occurrence and development, etc., targeting therapy with TFRC. |
I001137 | H11-hB2M&HLA-A24 | C57BL/6NCya | Research on human viral infectious diseases; development and testing of novel viral vaccines; safety and immunogenicity testing of drugs and vaccines; research on oncology and autoimmune diseases; research on the interaction mechanisms between human immune cells and pathogens; research on allogeneic tumor transplantation. |
I001138 | H11-hB2M&HLA-A2.1 | C57BL/6NCya | Research on human viral infectious diseases; development and testing of novel viral vaccines; safety and immunogenicity testing of drugs and vaccines; research on oncology and autoimmune diseases; research on the interaction mechanisms between human immune cells and pathogens; research on allogeneic tumor transplantation. |
I001139 | H11-hB2M&HLA-A11 | C57BL/6NCya | Research on human viral infectious diseases; development and testing of novel viral vaccines; safety and immunogenicity testing of drugs and vaccines; research on oncology and autoimmune diseases; research on the interaction mechanisms between human immune cells and pathogens; research on allogeneic tumor transplantation. |
I001187 | B6-hDPP4(line 1) | C57BL/6NCya | DPP4 inhibition therapy, research on MERS-CoV infection, research on SARS-CoV infection. |
I001188 | B6-hDPP4(line 2) | C57BL/6JCya | DPP4 inhibition therapy, research on MERS-CoV infection, research on SARS-CoV infection. |
I001189 | BALB/c-hDPP4(line 2) | BALB/cAnCya | DPP4 inhibition therapy, research on MERS-CoV infection, research on SARS-CoV infection. |
I001007 | B6N-hFCRN (Extra) | C57BL/6NCya | In vivo studies of human IgG antibodies, screening of IgG antibody candidate drugs, and evaluation of pharmacology, efficacy, and pharmacokinetics. |
I001020 | hCLDN18.2 | C57BL/6NCya | Development of CLDN18.2 targeted drugs and research on gastrointestinal malignancies. |
I001222 | B6-hPCSK9(CDS) | C57BL/6NCya | PCSK9-targeted Therapies, Metabolic Disease Research |
I001186 | B6-hFcRn(Extra)/hALB(HSA) | C57BL/6NCya | Pharmacology, Pharmacodynamics, and Pharmacokinetics |
I001180 | B6-hMMP7 | C57BL/6JCya | MMP7-targeted Drugs, Cancer Research, Fibrotic Disease Research |
C001571 | B6-hCD3/hCD20 | C57BL/6NCya |
|
C001588 | TG-hAPOC3 | C57BL/6NCya | Hypertriglyceridemia (HTG) |
C001592 | B6-hMASP2 | C57BL/6NCya | Autoimmune and infectious diseases |
C001603 | B6-hTL1A(TNFSF15) | C57BL/6JCya |
|
C001598 | B6-hPD-1/hVEGFA | C57BL/6JCya |
|
C001599 | B6-hGIPR/hGLP-1R | C57BL/6NCya |
|
C001605 | B6-hIL6 | C57BL/6NCya |
|
C001606 | B6-hIL6RA | C57BL/6NCya |
|
C001607 | B6-hIL6/IL6RA | C57BL/6NCya |
|
CR006 | SD-hSCN10A(Nav1.8) | Sprague-Dawley |
|
C001604 | B6-h4-1BB(TNFRSF9) | C57BL/6NCya |
|
C001627 | B6-hHER2(ERBB2) | C57BL/6NCya |
|